Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Lotemax Post-Marketing Surveillance
NCT01437982Phase 4Completed
- Sponsor
- Bausch + Lomb
- Start
- Aug 2010
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of loteprednol etabonate ophthalmic gel 0.38% in seasonal allergic conjunctivitis (SAC), giant papillary conjunctivitis (GPC) and post-operative ocular inflammation (2 arms), sponsored by Bausch + Lomb. Primary endpoint: Adverse Events and Adverse Drug Reactions at 4 years. Started Aug 2010; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
seasonal allergic conjunctivitis (SAC)giant papillary conjunctivitis (GPC)post-operative ocular inflammation
Beyond the preview
Go deeper on NCT01437982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437982.